Companies › Riboscience
1 active drug program in 3 registered trials: 2 Phase 2, 1 Phase 1; Oncology; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| RBS2418 Ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1) inhibitor that increases cGAMP | ENPP1 | Phase 2 | Advanced Unresectable Hepatocellular Carcinoma; Metastatic Colorectal Cancer; Advanced Cancer | Apr 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07175441 | RBS2418 | Phase 2 | Advanced Unresectable Hepatocellular Carcinoma | Oncology | Apr 2027 |
| NCT05270213 | RBS2418 | Phase 1 | Advanced Cancer | Oncology | Apr 2027 |
| NCT06824064 | RBS2418 | Phase 2 | Metastatic Colorectal Cancer | Oncology | Dec 2027 |
iOnctura Toray Industries SynerGene Therapeutics Lyvgen Biopharma Holdings Imvax
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.